FOLH1 and metastatic prostate carcinoma: We retrospectively evaluated the safety and therapeutic response of patients who received 177Lu-PSMA and/or 225Ac-PSMA in hormone sensitive or early-stage metastatic prostate cancer, mostly prior to initiation of hormonal therapy.